Acasti Pharma reported $-3.01M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
Acasti Pharma USD -3.01M 562K Mar/2026
Addus HomeCare USD 51.25M 2.08M Sep/2026
Amarin USD 12.54M 28.57M Jun/2025
Cassava Sciences USD -11.73M 33.44M Sep/2025
Knight Therapeutics CAD 24.45M 3.46M Dec/2025
Option Care Health USD 124.6M 7.12M Sep/2026
Organigram Holdings CAD 15.45M 20.21M Jun/2026
Tilray USD 8.36M 1.82M Sep/2025